Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Core Viewpoint - Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. related to alleged fiduciary breaches concerning the Phase 3 EFZO-FIT clinical trial disclosures [1][2] Investigation Background - The investigation covers the period from November 7, 2024, to September 12, 2025, focusing on allegations that aTyr and certain executives made false and/or misleading statements regarding the Phase 3 trial results [2][3] - Following the negative results from the Phase 3 trial, aTyr's stock price experienced a significant decline [2] Board Oversight - The investigation is examining whether aTyr's board failed to adequately oversee clinical disclosure controls and allowed overly optimistic representations that could expose the company to litigation and reputational risks [3] Shareholder Guidance - Current aTyr shareholders who held their shares continuously before November 7, 2024, may have the standing to pursue derivative claims on behalf of the company [2]